Stoke Therapeutics, Inc. STOK Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s other income, net (note 6)?
- Stoke Therapeutics, Inc. (STOK) reported other income, net (note 6) of $18K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
- Stoke Therapeutics, Inc.'s other income, net (note 6) decreased by 35.7% year-over-year, from $28K to $18K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other income, net (note 6)?
- Over 3 years (2021 to 2025), Stoke Therapeutics, Inc.'s other income, net (note 6) has grown at a -28.6% compound annual growth rate (CAGR), from $140K to -$51K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.